ATE69383T1 - Verfahren zur herstellung eines tollwutimpfstoffes und nach diesem verfahren erhaltener impfstoff. - Google Patents

Verfahren zur herstellung eines tollwutimpfstoffes und nach diesem verfahren erhaltener impfstoff.

Info

Publication number
ATE69383T1
ATE69383T1 AT86110116T AT86110116T ATE69383T1 AT E69383 T1 ATE69383 T1 AT E69383T1 AT 86110116 T AT86110116 T AT 86110116T AT 86110116 T AT86110116 T AT 86110116T AT E69383 T1 ATE69383 T1 AT E69383T1
Authority
AT
Austria
Prior art keywords
viruses
vaccine
rabies
nerve tissue
embryos
Prior art date
Application number
AT86110116T
Other languages
English (en)
Inventor
Reinhard Dr Phil Nat Glueck
Rene Prof Dr Phil Na Germanier
Original Assignee
Schweiz Serum & Impfinst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweiz Serum & Impfinst filed Critical Schweiz Serum & Impfinst
Application granted granted Critical
Publication of ATE69383T1 publication Critical patent/ATE69383T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT86110116T 1985-11-22 1986-07-23 Verfahren zur herstellung eines tollwutimpfstoffes und nach diesem verfahren erhaltener impfstoff. ATE69383T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH499985 1985-11-22
EP86110116A EP0222974B1 (de) 1985-11-22 1986-07-23 Verfahren zur Herstellung eines Tollwutimpfstoffes und nach diesem Verfahren erhaltener Impfstoff

Publications (1)

Publication Number Publication Date
ATE69383T1 true ATE69383T1 (de) 1991-11-15

Family

ID=4286207

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86110116T ATE69383T1 (de) 1985-11-22 1986-07-23 Verfahren zur herstellung eines tollwutimpfstoffes und nach diesem verfahren erhaltener impfstoff.

Country Status (9)

Country Link
EP (1) EP0222974B1 (de)
JP (1) JPS62129225A (de)
AT (1) ATE69383T1 (de)
AU (1) AU593041B2 (de)
CA (1) CA1271708A (de)
DE (1) DE3682482D1 (de)
ES (1) ES2000065A6 (de)
PT (1) PT83543B (de)
ZA (1) ZA866846B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN030794A0 (en) 1994-12-22 1995-01-27 Aruba International Pty Ltd Discontinuous plasma or serum delipidation
AUPQ486699A0 (en) * 1999-12-23 2000-02-03 Aruba International Pty Ltd A method of treating infectious diseases
US7407663B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7407662B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
AU2002322284A1 (en) 2001-06-25 2003-01-08 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
EP1567188B1 (de) * 2003-06-20 2012-07-11 Eli Lilly And Company Modifizierte virusteilchen mit immunogeneneigenschaften und verringertem lipidgehalt zur behandlung und prävention von infektionskrankheiten
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
JP2007527387A (ja) 2003-07-03 2007-09-27 リピッド サイエンシーズ，インコーポレイテッド 脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置
EP3714039B1 (de) 2017-11-22 2025-03-12 HDL Therapeutics, Inc. Verfahren zum primen von fluidkreisläufen eines plasmabearbeitungssystems
AU2018396009A1 (en) 2017-12-28 2020-07-16 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3143470A (en) * 1961-04-24 1964-08-04 Parke Davis & Co Rabies virus propagation in embryonic cells maintained in a medium containing pancreatic digest of casein
CH638985A5 (de) * 1979-04-10 1983-10-31 Schweiz Serum & Impfinst Verfahren zur herstellung eines tollwutimpfstoffes und danach erhaltener impfstoff.
US4347239A (en) * 1980-07-30 1982-08-31 Norden Laboratories, Inc. Inactivated rabies vaccine for veterinary use

Also Published As

Publication number Publication date
PT83543B (pt) 1988-11-30
ZA866846B (en) 1987-04-29
CA1271708A (en) 1990-07-17
PT83543A (fr) 1986-11-01
AU6563086A (en) 1987-05-28
JPH0586934B2 (de) 1993-12-14
EP0222974B1 (de) 1991-11-13
AU593041B2 (en) 1990-02-01
DE3682482D1 (de) 1991-12-19
EP0222974A3 (en) 1989-06-14
ES2000065A6 (es) 1987-11-16
EP0222974A2 (de) 1987-05-27
JPS62129225A (ja) 1987-06-11

Similar Documents

Publication Publication Date Title
ATE69383T1 (de) Verfahren zur herstellung eines tollwutimpfstoffes und nach diesem verfahren erhaltener impfstoff.
Strumwasser et al. A seasonal rhythm in the neural extract induction of behavioral egg-laying in Aplysia
Zhang et al. Isolation of chicken embryonic stem cell and preparation of chicken chimeric model
Shein Neoplastic transformation of hamster astrocytes in vitro by simian virus 40 and polyoma virus
DE2616407C3 (de) Verfahren zur Herstellung eines Tollwut-Impfstoffs
EP0067697A1 (de) Zellkultur-Verfahren
Cutress et al. Development of the Cubomedusae Carybdea marsupialis
Winter et al. DDT-lipoprotein complex in the American cockroach hemolymph: A possible way of insecticide transport
DE69018813D1 (de) Verfahren zur herstellung eines transgenen; nicht humanen tieres durch das ein- bringen von exogener dna in tierzellen; die somatischen und keimbahn ursprung haben.
ATE100495T1 (de) Rekombinantes marek-krankheitsvirus, verfahren zu seiner herstellung, und vakzine.
GB930451A (en) Process for propagating rabies virus
DE3867019D1 (de) Verfahren zur herstellung eines propolis-aethanolextraktes.
Beadle et al. Carbon dioxide narcosis
KR980000013A (ko) 곤충을 이용한 동충하초 버섯 종균의 배양방법
CN108977389A (zh) 一种在螺旋藻养殖过程中杀灭轮虫的方法
Sperry Reimplantation of eyes in fishes (Bathygobius soporator) with recovery of vision.
Ellis et al. Is there new hope for hormone mimics as pesticides?
GB1001689A (en) Process for the production of a rabies vaccine
DE2213709A1 (de) Verfahren zur Herstellung eines Interferonerzeugers
CN107549094A (zh) 一种林蛙饲养方法
SU1725904A1 (ru) Способ получени бруцеллезной вакцины из штамма 82
Swain Field days: Journal of an itinerant biologist
SU1317021A1 (ru) Штамм диплоидных клеток кожи и мышц эмбриона человека,используемый дл культивировани вирусов
Izawa et al. Herpesviral Isolates Related to Marek's Disease Virus from Chicken and Turkey Kidney Cell Cultures
Maier et al. The effect of limiting light to the pineal on the rate of forelimb regeneration in the newt

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee